AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Data from trial of EP-2101 released at ASCO.
2004 JUL 7 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (EPMN) provided preliminary data from ongoing phase I/II clinical trials of its EP-2101 therapeutic vaccine in non-small cell lung (NSCL) cancer and colorectal cancer patients in a poster presentation at the American Society of Clinical Oncology (ASCO) meeting in New Orleans.
The initial data from 10 patients who have completed treatment indicates that the vaccine was safe and well tolerated, and induced a multi-epitope response with 60% of the patients responding to at least five of the nine epitopes included in the vaccine. The company will complete analysis of the final data once the remaining patients enrolled in the trials have completed treatment.
Epimmune is conducting two phase I/II clinical trials of its EP-2101 cancer vaccine candidate at approximately 10 clinical sites in the U.S. One trial enrolled stage IIB/IIIA NSCL cancer patients, and the other trial enrolled stage III colorectal cancer patients.
The cancer vaccine candidate used in these trials includes nine cytotoxic T lymphocyte (CTL) epitopes from four tumor-associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes. The analog epitopes are designed to break the immune system's tolerance of the cancer, or failure to recognize the cancer as diseased tissue, and enhance the potency of the T cell response.
PADRE, the company's proprietary universal helper T lymphocyte (HTL) epitope, is also included in the vaccine as an immunostimulant. Patients enrolled in the trials have previously had surgery to remove all detectable cancer cells and, as a result, are generally expected to have normal immune system function. Each patient who completes the trial receives six injections of the vaccine at 3-week intervals.
To date, the company has enrolled a total of 24 patients combined in the two trials and expects that approximately 16 of the 24 patients will complete the treatment and be evaluable at the end of the trials based on pre-determined study criteria. Based on 10 patients who have completed treatment and been evaluated to date, EP-2101 appears to be safe and well tolerated.
In addition, ...
- XOMA Initiates Phase I Study of ING-1 in Cancer Patients.
- Press release article from: Business Wire November 1, 2000 700+ words
...TM) monoclonal antibody in cancer patients. ING-1 could potentially...binds with high affinity to the Ep-CAM antigen. Once bound to Ep-CAM, the ING-1 antibody...cell death. High levels of Ep-CAM are expressed on the great...
- Market for Peripheral Neuropathy Among Diabetics, HIV/AIDS and Cancer Patients...
- Press release article from: PR Newswire November 20, 2003 700+ words
...Quigley Corporation), with undefined mechanisms of action. Worldwide Peripheral Neuropathy is a newly released report from EP Publications, a service of WWMR (Worldwide Marketing Research), Inc., http://www.wwmr.com/ , forecasting the value...
- Market for Peripheral Neuropathy Among Diabetics, HIV/AIDS and Cancer Patients...
- Press release article from: PR Newswire November 20, 2003 700+ words
...Quigley Corporation), with undefined mechanisms of action. Worldwide Peripheral Neuropathy is a newly released report from EP Publications, a service of WWMR (Worldwide Marketing Research), Inc., http://www.WWMR.com , forecasting the value...
- Peripheral Neuropathy Market Approaches $1B by 2012; Diabetics, HIV/AIDS and...
- Press release article from: PR Newswire April 7, 2004 700+ words
SAN FRANCISCO, April 7 /PRNewswire/ -- Worldwide Peripheral Neuropathy is a recently released report from EP Publications, a service of WWMR (Worldwide Marketing Research), Inc. This report forecasts the value of the peripheral neuropathy...
- Data from trial of EP-2101 released at ASCO.
- Newspaper article from: Respiratory Therapeutics Week July 5, 2004 700+ words
...clinical trials of its EP-2101 therapeutic...cancer and colorectal cancer patients in a poster presentation...clinical trials of its EP-2101 cancer vaccine...IIB/IIIA NSCL cancer patients, and the other...phase II trial of EP-2101 in late stage...NSCL or colorectal ...
- IDM Pharma Presents Interim Phase II Data From EP-2101 Lung Cancer Vaccine...
- Press release article from: PR Newswire June 4, 2007 700+ words
...survival for patients treated with EP-2101 was 583 days compared...percent of patients treated with EP-2101, who were tested for...novel approach to treating lung cancer patients and these positive interim results...appropriate clinical pathway for EP-2101 as both a single-agent...
- IDMI Announces Interim Data From Phase II Study of EP-2101 Lung Cancer Vaccine...
- Press release article from: M2 Presswire June 4, 2007 700+ words
...survival for patients treated with EP-2101 was 583 days compared...percent of patients treated with EP-2101, who were tested for...novel approach to treating lung cancer patients and these positive interim results...appropriate clinical pathway for EP-2101 as both a single-agent...
- IDM Pharma Announces Interim Phase II Data From EP-2101 Lung Cancer Vaccine...
- Press release article from: M2 Presswire June 4, 2007 700+ words
...survival for patients treated with EP-2101 was 583 days compared...percent of patients treated with EP-2101, who were tested for...novel approach to treating lung cancer patients and these positive interim results...appropriate clinical pathway for EP-2101 as both a single-agent...
Source: HighBeam Research, Data from trial of EP-2101 released at ASCO.